Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1192-1198

  Hili, David S ^a   Martin, Shaun ^a   Armstrong, Jane L ^a   Flockhart, Ross ^a   Tonison, Joge J ^a   Simpson, Dominic G ^a   Birch Machin, Mark A ^a   Redfern, Christopher P F ^a,b   Lovat, Penny E ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; FENRETINIDE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; KI 67 ANTIGEN; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL DIVISION; CELL SURVIVAL; ENDOPLASMIC RETICULUM; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; ENDOPLASMIC RETICULUM; FEMALE; FENRETINIDE; G2 PHASE; HUMANS; KI-67 ANTIGEN; MELANOMA; MICE; PYRAZINES;

EID: 63149188611     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2150     Document Type: Article

References (38)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701.
2. Rass K, Tilgen W. Treatment of melanoma and non melanoma skin cancer. Adv Exp Med Biol 2008;624: 296-318.
3. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6: 185-93.
4. Quirt I, Verma S, PetrellaT Bak K, Charette M. Temo-zolomide for the treatment of metastatic melanoma: a systemic review. Oncologist 2007;12:1114-23.
5. Xiao C, Yang BF, Song JH, Schulman H, Li L, Hao C. Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Exp Cell Res 2005;304:244-55.
6. Karst AM, Dai DL, Martinka M, Li G. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 2005:24:1111-6.
7. Piro LD. Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology 2004;18:5-10.
8. Denoyelle C, Abou-Rjaily G, Bezrookove V, et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006;8:1053-63.
9. Corazzari M, Lovat PE, Armstrong JL, et al. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase suseptibility of cancer cells to fenre-tinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer 2007;96:1062-71.
10. Lovat PE, Corazzari M, Armstrong JL, et al. Increasing melanoma cell death using inhibitors of protein disulphide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res 2008;68: 5363-9.
11. Markovic SN, Geyer SM, Dawkins F, et al. A phase II study of bortezomib in the treatment of malignant melanoma. Cancer 2005;103:2584-9.
12. Amiri Kl, Norton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteosome inhibition: implication for Bortexomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004;64:4912-8.
13. Nawrocki ST, CarewJS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005;65:11658-66.
14. Kadara H. Tahara E, Kim HJ, Lotan D, MyersJ, Lotan R. Involvement of Rac in fenretinide-induced apoptosis. Cancer Res 2008;68:4416-23.
15. Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL, Jr. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest New Drugs 1990;8:317-9.
16. Al-Daraji Wl, Grant KR, Ryan K, Saxton A, Reynolds NJ. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFATactivation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002;118:779-88.
17. Marconi G, Quintana R. Methylene blue dyeing of cellular nuclei during salpingoscopy, a new in-vivo method to evaluate vitality of tubal epithelium. Hum Reprod 1998;13:3414-7.
18. Chou T-C. The median-effect principle and the combination index for quantification of synergism and antagonism. In: Chou T-C, Rideout DC, editors. Synergism and antagonism in chemotherapy. San Diego: Academic Press; 1991. p. 61-102.
19. Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol CancerTher 2002;1:841-9.
20. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004; 11:381-9.
21. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007;56:275-87.
22. Hoeflich KP, Gray DC, Eby MT, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006;66:999-1006.
23. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-53.
24. Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005;24:344-54.
25. Brignole C, Marimpietri D, Pastorino F, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006;98:1142-57.
26. Kincaid MM, Cooper AA. ERADicate ER stress or die trying. Antioxid Redox Signal 2007;9:2373-87.
27. Nawrocki ST, CarewJS, Dunner K, Jr.,et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65:11510-9.
28. Nawrocki ST, CarewJS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81.
29. Kraus M, Malenke E, Gogel J, et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol CancerTher 2008;7:1940-8.
30. Garaventa A, Luksch R, Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003;9: 2032-9.
31. Otterson GA, Lavelle J, Villalona-Calero MA, et al. A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors. Invest New Drugs 2005; 23:555-62.
32. Formelli F, Cavadini E, Luksch R, et al. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol 2008;62: 655-65.
33. Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008; 14:1446-54.
34. HortonTM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res 2007;13:1516-22.
35. Ogawa Y Tobinai K, Ogura M, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci 2008;99:140-4.
36. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-21.
37. Wolter KG, Verhaegen M, Fernandez Y, et al. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 2007;14:1605-16.
38. Tagscherer KE, Fassl A, Campos B, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008;27:6646-56.